

# CURRICULUM VITAE



## PERSONAL INFORMATION

Name **CLAUDIA CECI**

E-mail Address **claudiaceci@hotmail.it**  
**claudia.ceci@unicamillus.org**

Nationality Italian

Date and place of birth 05/07/1985, VEROLI (FR)

## RESEARCH EXPERIENCE

Date **OCTOBER 2022 – TO DATE**  
Name of employer UniCamillus International Medical University in Rome  
Type of business or sector Departmental Faculty of Medicine and Surgery  
Occupation or position held Type A Researcher  
Main activities and responsibilities Direct participation in every phase of the research project entitled “Conjugation of a novel humanized monoclonal antibody anti-VEGFR-1 with a cytotoxic compound”.

Date **DECEMBER 2021 – SEPTEMBER 2022**  
Name of employer University of Rome Tor Vergata  
Type of business or sector Medical School, Department of Systems Medicine, laboratory of Pharmacology  
Occupation and position held Winner of a Research Grant entitled “Conjugation of a novel humanized monoclonal antibody anti-VEGFR-1 with a cytotoxic compound” (Banca d’Italia – code F1-2021-0067)  
Main activities and responsibilities Direct participation in every phase of the research project

Date **FEBRUARY 2018 - NOVEMBER 2021**  
Name of employer Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)  
Type of business or sector Medical School, Department of Systems Medicine, laboratory of Pharmacology,  
University of Rome Tor Vergata  
Occupation and position held Research collaboration  
Main activities and responsibilities - Direct participation in every phase of the research project entitled “Antitumor activity of ellagic acid derivatives”.  
- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled “Validation and humanization of a novel anti-VEGFR-1 monoclonal antibody for malignant melanoma treatment” (AIRC, Investigator Grant IG 2017 N. 203553)

Date **FEBRUARY 2016 - JULY 201**  
Name of employer University of Rome Tor Vergata  
Type of business or sector Medical School, Department of Systems Medicine, laboratory of Pharmacology

Occupation and position held	Post-doctoral fellow entitled "Antiproliferative and apoptotic activity of ellagic acid in cell models of bladder cancer"; D.R. n.3102 del 02/11/2015.
Main activities and responsibilities	<ul style="list-style-type: none"> <li>- Direct participation in every phase of the research project in collaboration with Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)</li> <li>- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled targeting of VEGFR-1 and PARP-1 to reduce chemoresistance of glioblastoma and glioblastoma stem cells (AIRC, Investigator Grant IG 2013 N. 14042)</li> </ul>
Date	<b>DECEMBER 2014 – DECEMBER 2015</b>
Name of employer	Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation and position held	University of Rome Tor Vergata
Main activities and responsibilities	<p>Research collaboration</p> <ul style="list-style-type: none"> <li>- Direct participation in every phase of the research project focused on the characterization of ellagic acid anticancer potential</li> <li>- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled targeting of VEGFR-1 and PARP-1 to reduce chemoresistance of glioblastoma and glioblastoma stem cells (AIRC, Investigator Grant IG 2013 N. 14042)</li> </ul>
Date	<b>DECEMBER 2011 - NOVEMBER 2014</b>
Name of employer	University of Rome Tor Vergata
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Neuropsychopharmacology
Occupation and position held	PhD student in Neuroscience
Main activities and responsibilities	<p>Direct participation in every phase of the research project, from programming to laboratory activities [Aim of the study: nickel exposure effect on neuronal differentiation]</p>
Date	<b>NOVEMBER 2010 - APRIL 2011</b>
Name of employer	University of Rome Tor Vergata
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Neuropsychopharmacology
Occupation and position held	Pre-doctoral fellow, entitled "Epigenetic regulation and neural differentiation"; D.R. n.3510 del 6/10/2010
Main activities and responsibilities	Direct participation in every phase of the research project
Date	<b>NOVEMBER 2008 - MAY 2010</b>
Name of employer	University of Rome Tor Vergata
Type of business or sector	Faculty of Mathematical, Physical and Natural Sciences, Department of Biology, laboratory of cell and developmental biology
Occupation and position held	Graduating student for the degree (II level) in Cell and Molecular Biology
Main activities and responsibilities	Direct participation in every phase of the experimental thesis project and laboratory activities
Date	<b>MARCH 2007 - JUNE 2007</b>
Name of employer	University of Rome Tor Vergata
Type of business or sector	Faculty of Mathematical, Physical and Natural Sciences, Department of Biology, laboratory of Biochemistry
Occupation and position held	Graduating student for the degree (I level) in Cell and Molecular Biology
Main activities and responsibilities	Direct participation in laboratory activities

## EDUCATION AND TRAINING

Date	<b>DECEMBER 2011 - MAY 2014</b>
Name and type of organization providing education and training	University of Rome Tor Vergata, School of Medicine
Main subjects / professional abilities	Neuroscience, Developmental and cell biology
Title of qualification awarded	PhD in Neurosciences, Thesis title: "Effect of nickel exposure on neuronal differentiation"
Date	<b>OCTOBER 2007 - MAY 2010</b>
Name and type of organization providing education and training	University of Rome Tor Vergata; Faculty of Mathematical, Physical and Natural Sciences
Main subjects / professional abilities	Developmental and cell biology, biochemistry, genetic, molecular biology
Title of qualification awarded	Degree in Cellular and Molecular Biology, 110/110 <i>cum laude</i>
Level in national classification	Second level specialistic degree Thesis title: "Reticulon 1-C effect in chemotherapeutic treatment of human mammal adenocarcinoma MCF-7 cells"
Date	<b>OCTOBER 2004 - OCTOBER 2007</b>
Name and type of organization providing education and training	University of Rome Tor Vergata; Faculty of Mathematical, Physical and Natural Sciences
Main subjects / professional abilities	Genetics, biochemistry, cell biology, molecular biology
Title of qualification awarded	Degree in Cellular and Molecular Biology, 110/110 <i>cum laude</i>
Level in national classification	First level degree Thesis title "Human DNA Topoisomerase I: analysis of mutations that could render the enzyme resistant to the anticancer agent camptothecin"
Date	<b>SEPTEMBER 1999 - JUNE 2004</b>
Name and type of organization providing education and training	Scientific High School "Giovanni Sulpicio" in Veroli (Frosinone, Italy), socio-psycho-pedagogical address
Title of qualification awarded	High School Diploma, 100/100

## TEACHING EXPERIENCE

- Lecturer of lessons concerning "Cellular and Molecular Pharmacology" and "Pharmacogenomics", Degree Course in Pharmacy, Cyprus International University, Summer Semester 2022.
- "Pharmaceutical Toxicology and galenic Pharmacology" Course Owner, Degree Course in Biomedical Laboratory Techniques, UniCamillus International Medical University in Rome (3 CFU, a.y. 2022/2023).
- "Pharmacology" Course Owner, Degree Course in Medicine and Surgery, UniCamillus International Medical University in Rome (5 CFU, a.y. 2020/2021, 2021/2022, 2022/2023).
- "Pharmacology" Course Owner, Degree Course in Midwifery, UniCamillus International Medical University in Rome (1 CFU, a.y. 2019/2020, 2020/2021, 2021/2022, 2022/2023).
- "Special Pharmacology and Therapy - Module I" Course Owner, Degree Course in Pharmacy, University of Rome Tor Vergata (5 CFU, a.y. 2018/2019, 2019/2020, 2020/2021, 2021/2022, 2022/2023).
- Substituting Teacher, Scientific High School "Giovanni Sulpicio", in Veroli (FR), October-November 2018.
- Lecturer of lessons concerning chemotherapy, anticoagulants and anti-inflammatory drugs; Degree Courses in Health Professions, University of Rome Tor Vergata (a.y. 2012/2013 and 2013/2014).

	- Co-relator of Experimental and Theoretical Thesis, Degree Course in Pharmacy, University of Rome Tor Vergata.
<b>PERSONAL SKILLS AND COMPETENCE</b>	
MOTHER TONGUE	<b>ITALIAN</b>
OTHER LANGUAGES	
	<b>ENGLISH</b>
Reading	GOOD
Writing	GOOD
Oral Expression	GOOD
	<b>FRENCH</b>
Reading	GOOD
Writing	SUFFICIENT
Oral Expression	SUFFICIENT
<b>TECHNICAL SKILLS AND COMPETENCE</b>	<ul style="list-style-type: none"> <li>- EUKARYOTIC CELL CULTURES</li> <li>- TREATMENT WITH ANTICANCER DRUG AND VIABILITY ASSAYS</li> <li>- BACTERIAL CULTURES AND TRANSFORMATION</li> <li>- DNA AND PROTEINS EXTRACTION</li> <li>- WESTERN BLOT</li> <li>- IMMUNOFLUORESCENCE</li> <li>- IMMUNOPRECIPITATION</li> <li>- PCR</li> <li>- ELISA</li> <li>- TRANSFECTIONS</li> <li>- CELL INVASION AND MIGRATION ASSAYS</li> <li>- PRE-CLINICAL CHARACTERIZATION IN MURINE MODELS OF ANTICANCER DRUGS AND COMPOUNDS FROM THE DIET ANTIPROLIFERATIVE ACTIVITY</li> </ul>
<b>EDITORIAL ACTIVITY</b>	Since September 2020, Editorial Board Member of scientific journal "Chemotherapy" (Kanger)
<b>MEMBERSHIP IN SCIENTIFIC SOCIETIES</b>	Since June 2021, Member of Pharmacology Italian Society
<b>PATENTS</b>	Co-author (5%) of the patent entitled "Microsfere di idrogeli di polimeri polisaccaridici contenenti cellule neurali secernenti dopamina, procedimento per la loro preparazione e loro usi in campo medico", number RM2013A000572.

## PUBLICATIONS

Garufi A, Pistritto G, **Ceci C**, Di Renzo L, Santarelli R, Faggioni A, Cirone M, D'Orazi G. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. *PLoS One*. 2012;7(11).

Pistritto G, Papaleo V, Sanchez P, **Ceci C**, Barbaccia ML. Divergent modulation of neuronal differentiation by Caspase-2 and -9. *PLoS One*. 2012;7(5).

**Ceci C**, Barbaccia ML, Pistritto G. A not cytotoxic nickel concentration alters the expression of neuronal differentiation markers in NT2 cells. *Neurotoxicology*. 2015;47:47-53.

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, **Ceci C**, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM (2015). A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. *Biochem Pharmacol*. 95(1):16-27.

Pistritto G, Trisciuglio D, **Ceci C**, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging (Albany NY)*. 2016 (4):603-19.

**Ceci C**, Tentori L, Atzori MG, Lecal PM, Bonanno E, Scimeca M, Cicconi R, Mattei M, de Martino MG, Vespasiani G, Miano R, Graziani G (2016). Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. *Nutrients* 8(11).

Atzori MG, Tentori L, Ruffini F, **Ceci C**, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, Ricci Vitiani L, Pallini R, Navarra P, Bjerkvig R, D'Atri S, Lecal PM, Graziani G. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. *J Exp Clin Cancer Res*. 2017; 36(1):106.

Cacciotti I, **Ceci C**, Bianco A, Pistritto G. Neuro-differentiated Ntera2 cancer stem cells encapsulated in alginate beads: First evidence of biological functionality. *Mater Sci Eng C Mater Biol Appl*. 2017;81:32-38.

Atzori MG, Tentori L, Ruffini F, **Ceci C**, Bonanno E, Scimeca M, Lecal PM, Graziani G. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. *J Pharmacol Exp Ther*. 2018; 364(1):77-86.

**Ceci C**, Lecal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. *Nutrients*. 2018; 10(11).

Atzori MG, **Ceci C**, Ruffini F, Trapani M, Barbaccia ML, Tentori L, D'Atri S, Lecal PM, Graziani G. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib. *J. Cell. Mol. Med*. 2020, 24, 465-475.

**Ceci C**, Atzori MG, Lecal, PM, Graziani, G. Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models. *Int J Mol Sci*. 2020; 21(4):1338.

**Ceci C**, Graziani G, Faraoni I, Cacciotti I. Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriers. *Nanotechnology*. 2020; 31(38): 382001.

**Ceci C**, Atzori MG, Lecal PM, Graziani G. Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. *Cancers (Basel)*. 2020;12(11):3401.

**Ceci C**, Lecal PM, Graziani G. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. *Pharmacol Ther*. 2022;236:108106.

Rome, October 21, 2022

